Logo

NIDDK Announces Proteomics/Metabolomics Project in Type 2 Diabetes

Mar 19, 2004

NEW YORK, March 19 (GenomeWeb News) - The National Institute of Diabetes and Digestive and Kidney Diseases announced today that it will commit $1 million in FY 2005 to fund projects devoted to using proteomic and metabolomic techniques to develop a diagnostic for type 2 diabetes.

 

Applicants can request funding for two years under the R21 mechanism, followed by three years under the R33 mechanism. The application receipt date for this PAR is July 20, 2004.

 

In addition to funding, the NIDDK will provide to investigators plasma from diverse individuals for use in validation experiments. Plasma from three types of patients will be provided: those who have been diagnosed with type 2 diabetes; those who have impaired glucose tolerance, and those who have normal glucose tolerance.

 

The newest PAR is one of several that the NIDDK has issued over the past couple of years inviting investigators to apply proteomics to the study of diabetes.

 

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.